Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(5):330; doi:10.1093/jnci/94.5.330
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Fintor, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fintor, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 5, 330, March 6, 2002
© 2002 Oxford University Press

NEWS

AstraZeneca Reprimanded for Nolvadex Advertisement

Lou Fintor

In a December letter sent to pharmaceutical manufacturer AstraZeneca LP, the U.S. Food and Drug Administration said the company "promoted misleading efficacy information" and "minimized the risks" associated with their drug Nolvadex (tamoxifen citrate). The letter . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?